scholarly journals Comparison of the 2017 EULAR/ACR Criteria with Clinicoserologic Criteria for the Classification of Idiopathic Inflammatory Myopathies in Korean Patients

2021 ◽  
Vol 62 (5) ◽  
pp. 424
Author(s):  
Sang Wan Chung ◽  
In Seol Yoo ◽  
Jinhyun Kim ◽  
Seong Wook Kang ◽  
Mihye Kwon ◽  
...  
2019 ◽  
Vol 38 (7) ◽  
pp. 1931-1934 ◽  
Author(s):  
Benzeeta Pinto ◽  
Ramya Janardana ◽  
Raghunanadan Nadig ◽  
Anita Mahadevan ◽  
Anusha S. Bhatt ◽  
...  

2020 ◽  
Vol 33 (5) ◽  
pp. 590-603 ◽  
Author(s):  
Jantima Tanboon ◽  
Akinori Uruha ◽  
Werner Stenzel ◽  
Ichizo Nishino

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1573.2-1573
Author(s):  
F. Bozan ◽  
S. Saavedra ◽  
K. Vergara ◽  
A. Goecke ◽  
H. Gatica

Background:Differents classifications criteria for IIM exist. New classification criteria are superior to previous in capturing different subgroups of IIM.Objectives:To compare the concordance and disparity of Bohan and Peter and EULAR/ACR 2017 classification criteria at the level of diagnostic certainty, in a group of chilean patients with IIM.Methods:40 adults patients with IIM (27 Dermatomyositis (DM) and 13 Polimyositis (PM)), according Bohan and Peter criteria were analized. The patients were reclassified with EULAR/ACR criteria. The level of diagnostic certainty (definitive, probable and possible) was registered for both Classification Criteria. The concordance and disparity between criteria was evaluated. Concordance and disparity analysis were made considering the strict agreement between level of certainty of both criteria, using Cohen´s Kappa coefficient. The analysis was done for the complete cohort and for separated groups.Patients with discordance belonging to the same subgroup were evaluated using contingency tables. The direction of the change (gain or lost of certainty) and the relation with diagnostic subgroup was also analized. Descriptive statistics is expressed as diagnostic categories, number of patients and rates.Results:For the complete cohort and for DM and PM groups the concordance was low. For 27 patients with DM, the observed concordance rate was 63% (16 definitives, 1 probable). The observed disparity rate was 37%. The direction of the change was gain of one level of certainty in 14.5% and two levels in 22.2% of patients applying EULAR/ACR criteria compared to Bohan y Peter criteria. For 13 pacients with PM, the observed concordance rate was 46% (3 definitives and 3 probables). The observed disparity rate was 54%. The direction of the change was loss of certainty. The loss of certainty was one level in 85,7% (one patient change from probable to posible). Only one patiente had gain of certainty of one level (14.3%).Conclusion:The strict concordance between both classification criteria was low. The observed concordances were better in patients with DM that PM. The disparities involved gain of level of diagnostic certainty in DM patients, while in PM patients there was mostly lost of level of certainty.References:[1]Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). NEJM 1975;292:344-7.[2]Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). NEJM 1975;292:403-7.[3]2017 European League Against Rheumatism/American Colllege of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their major Subgroups. Arthritis Rheum 2017;0:1-12.Disclosure of Interests: :None declared


2016 ◽  
Vol 280 (1) ◽  
pp. 39-51 ◽  
Author(s):  
I. E. Lundberg ◽  
F. W. Miller ◽  
A. Tjärnlund ◽  
M. Bottai

2019 ◽  
Vol 19 (4) ◽  
pp. 284-294 ◽  
Author(s):  
Anke Rietveld ◽  
Johan Lim ◽  
Marianne de Visser ◽  
Baziel van Engelen ◽  
Ger Pruijn ◽  
...  

The diagnosis and classification of idiopathic inflammatory myopathies are based mainly on clinical and histological features. The discovery of myositis-specific and myositis-associated antibodies has simplified the (sub)classification of inflammatory myopathies. Patients suspected of having an idiopathic inflammatory myopathy should undergo routine antibody testing to gain more insight into distinct phenotypes, comorbidities, treatment response and prognosis. Furthermore, autoantibody testing can help in patients with atypical patterns of weakness or with an unresolved limb-girdle myopathic phenotype, or interstitial lung disease. However, some important technical and methodological issues can hamper the interpretation of antibody testing; for example, some antibodies are not included in the widely available line blots. We aim to provide a practical review of the use of autoantibody testing in idiopathic inflammatory myopathies in clinical practice.


Sign in / Sign up

Export Citation Format

Share Document